"Chenodeoxycholic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.
| Descriptor ID |
D002635
|
| MeSH Number(s) |
D04.210.500.105.225.272.150 D04.210.500.221.430.342.300
|
| Concept/Terms |
Chenodeoxycholic Acid- Chenodeoxycholic Acid
- Acid, Chenodeoxycholic
- Chenique Acid
- Acid, Chenique
- Gallodesoxycholic Acid
- Acid, Gallodesoxycholic
- Henohol
- Chenic Acid
- Acid, Chenic
- Chenodiol
|
Below are MeSH descriptors whose meaning is more general than "Chenodeoxycholic Acid".
Below are MeSH descriptors whose meaning is more specific than "Chenodeoxycholic Acid".
This graph shows the total number of publications written about "Chenodeoxycholic Acid" by people in this website by year, and whether "Chenodeoxycholic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chenodeoxycholic Acid" by people in Profiles.
-
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2022 03; 76(3):536-548.
-
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. Clin Gastroenterol Hepatol. 2022 09; 20(9):2050-2058.e12.
-
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019 12 14; 394(10215):2184-2196.
-
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials. 2019 09; 84:105803.
-
NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD. Nat Rev Gastroenterol Hepatol. 2015 Feb; 12(2):65-6.
-
Bile composition in Alagille Syndrome and PFIC patients having Partial External Biliary Diversion. BMC Gastroenterol. 2008 Oct 20; 8:47.
-
Early gallstone recurrence rate after successful shock-wave therapy. Gastroenterology. 1990 Feb; 98(2):392-6.